LianBio IPO: How to buy the stock of biotech firm focused on China?

3 min read | November 01, 2021 03:48 AM EDT | By Raza Naqvi

LianBio IPO: How to buy the stock of biotech firm focused on China? — Image source: © Prykhodov | Megapixl.com

Everything you need to know about LianBio IPO

Notably, the ADSs will reportedly start trading on the Nasdaq Global Market on Monday, November 1.

LianBio will trade under the stock symbol 'LIAN', and the offering will close by November 3, and the closing will be subjected to customary closing conditions.

How to buy LianBio stock?

The joint underwriters for the stock offering are BofA Securities, Jefferies LLC and Goldman Sachs & Co. LLC. Meanwhile, the leading underwriting responsibility for the IPO is on Raymond James.

Generally, a newly listed company starts trading one hour later after the markets open in the US or after 10 AM EST.

Also Read: Nexii Building Solutions IPO: Can you buy Nexiite-maker's stock?

Those interested in buying the LianBio stock, should track the Nasdaq and once it begins trading, investors may use stock trading apps to get hold of the stock.

Bottom line

In the US Securities and Exchange Commission (SEC) prospectus, LianBio claims that it is a cross-border biotechnology company, advancing a diversified portfolio of clinically validated products through partnerships with innovative biotechnology companies.

According to LianBio, China is the second-largest pharmaceutical market globally and generated a revenue of US$ 89 billion in 2020.

The market is expected to generate a revenue of US$ 187 billion by 2025, and the biotechnology companies have a growth potential due to the rapidly growing demand.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Incorporated (Kalkine Media), Business Number: 720744275BC0001 and is available for personal and non-commercial use only. The advice given by Kalkine Media through its Content is general information only and it does not take into account the user’s personal investment objectives, financial situation and specific needs. Users should make their own enquiries about any investment and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media is not registered as an investment adviser in Canada under either the provincial or territorial Securities Acts. Some of the Content on this website may be sponsored/non-sponsored, as applicable, however, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used in the Content unless stated otherwise. The images/music that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.